PL4419526T3 - Związki heterocykliczne do stosowania w leczeniu nowotworu - Google Patents

Związki heterocykliczne do stosowania w leczeniu nowotworu

Info

Publication number
PL4419526T3
PL4419526T3 PL22797829.3T PL22797829T PL4419526T3 PL 4419526 T3 PL4419526 T3 PL 4419526T3 PL 22797829 T PL22797829 T PL 22797829T PL 4419526 T3 PL4419526 T3 PL 4419526T3
Authority
PL
Poland
Prior art keywords
cancer
treatment
heterocyclic compounds
heterocyclic
compounds
Prior art date
Application number
PL22797829.3T
Other languages
English (en)
Inventor
Owen Davis
Robert Heald
Martin Stockley
Harry Finch
Sam MANN
Original Assignee
Artios Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artios Pharma Limited filed Critical Artios Pharma Limited
Publication of PL4419526T3 publication Critical patent/PL4419526T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995Pyrazines or piperazines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL22797829.3T 2021-10-21 2022-10-21 Związki heterocykliczne do stosowania w leczeniu nowotworu PL4419526T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2115156.8A GB202115156D0 (en) 2021-10-21 2021-10-21 Novel compounds
PCT/GB2022/052690 WO2023067356A1 (en) 2021-10-21 2022-10-21 Heterocyclic compounds for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
PL4419526T3 true PL4419526T3 (pl) 2025-04-22

Family

ID=78805918

Family Applications (1)

Application Number Title Priority Date Filing Date
PL22797829.3T PL4419526T3 (pl) 2021-10-21 2022-10-21 Związki heterocykliczne do stosowania w leczeniu nowotworu

Country Status (24)

Country Link
US (2) US20240425511A1 (pl)
EP (2) EP4419527A1 (pl)
JP (2) JP2024539132A (pl)
KR (1) KR20240099274A (pl)
CN (2) CN119053600A (pl)
AR (1) AR127431A1 (pl)
AU (1) AU2022374050A1 (pl)
CA (1) CA3233255A1 (pl)
DK (1) DK4419526T3 (pl)
ES (1) ES3008687T3 (pl)
FI (1) FI4419526T3 (pl)
GB (1) GB202115156D0 (pl)
HR (1) HRP20250334T1 (pl)
HU (1) HUE070568T2 (pl)
IL (1) IL311922A (pl)
LT (1) LT4419526T (pl)
MX (1) MX2024004874A (pl)
PL (1) PL4419526T3 (pl)
PT (1) PT4419526T (pl)
RS (1) RS66620B1 (pl)
SI (1) SI4419526T1 (pl)
SM (1) SMT202500123T1 (pl)
TW (1) TW202334150A (pl)
WO (2) WO2023067356A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025077896A1 (zh) * 2023-10-12 2025-04-17 上海湃隆生物科技有限公司 一种DNA聚合酶theta抑制剂及其应用
CN118084767B (zh) * 2024-04-02 2025-06-17 康龙化成手性医药技术(宁波)有限公司 一种外型-6-氟甲基-3-氮杂双环[3,1,0]己烷盐酸盐及其衍生物的合成方法
WO2025214463A1 (zh) * 2024-04-13 2025-10-16 正大天晴药业集团股份有限公司 含有三并环结构的化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017062754A1 (en) 2015-10-07 2017-04-13 New York University Compositions and methods for enhancing crispr activity by polq inhibition
EP4010080B1 (en) * 2019-08-09 2023-09-27 Artios Pharma Limited Heterocyclic compounds for use in the treatment of cancer

Also Published As

Publication number Publication date
US20260124214A1 (en) 2026-05-07
JP2024542949A (ja) 2024-11-19
EP4419526B1 (en) 2024-12-25
GB202115156D0 (en) 2021-12-08
IL311922A (en) 2024-06-01
RS66620B1 (sr) 2025-04-30
CN119053600A (zh) 2024-11-29
EP4419526A1 (en) 2024-08-28
US20240425511A1 (en) 2024-12-26
HRP20250334T1 (hr) 2025-06-06
SMT202500123T1 (it) 2025-05-12
TW202334150A (zh) 2023-09-01
ES3008687T3 (en) 2025-03-24
EP4419527A1 (en) 2024-08-28
AR127431A1 (es) 2024-01-24
SI4419526T1 (sl) 2025-05-30
MX2024004874A (es) 2024-05-06
JP2024539132A (ja) 2024-10-28
PT4419526T (pt) 2025-02-03
CA3233255A1 (en) 2023-04-27
DK4419526T3 (da) 2025-02-17
LT4419526T (lt) 2025-03-25
AU2022374050A1 (en) 2024-05-02
FI4419526T3 (fi) 2025-02-13
WO2023067356A1 (en) 2023-04-27
WO2023067355A1 (en) 2023-04-27
HUE070568T2 (hu) 2025-06-28
KR20240099274A (ko) 2024-06-28
CN118234728A (zh) 2024-06-21

Similar Documents

Publication Publication Date Title
IL316706A (en) Macrocycle compounds for cancer treatment
IL288104B1 (en) Heterocyclic compounds, pharmaceutical preparations containing them and their use for the treatment of cancer
IL290415A (en) Compounds with deuterium for use in cancer treatment
ES3065771T3 (en) Substituted oxoisoindoline compounds for the treatment of cancer
IL311922A (en) Heterocyclic compounds for use in cancer treatment
SI3806898T1 (sl) Antagonist Gremlin-1 za uporabo pri zdravljenju raka
ZA202206743B (en) Therapy for the treatment of cancer
IL280337A (en) LAG-3 combination therapy for cancer treatment
PL3601296T3 (pl) Pochodne 2-okso-tiazolowe jako inhibitory i związki a2a do stosowania w leczeniu nowotworów złośliwych
IL304595A (en) Bicyclic tetrahydrozepine derivatives for cancer treatment
IL307338A (en) Pyridinyl substituted oxisoisoindoline compounds for cancer therapy
IL312171A (en) Innovative use of the quinazolinone compound for cancer treatment
SG11202103141YA (en) Combination therapy for the treatment of cancer
SMT202500434T1 (it) Sotorasib per l'uso nel trattamento del cancro
IL321393A (en) CTPS1 inhibitors for use in the treatment of cancers with CTPS2 deficiency
IL284162A (en) Integrated healing for cancer treatment
GB202317288D0 (en) Pyrrolopyridone derivatives useful in the treatment of cancer
GB201918404D0 (en) Compounds and their use for the treatment of aplha1-antitrypsin deficiency
IL309172A (en) Vulbanazine for use in the additional treatment of schizophrenia
IL305780A (en) Cancer treatment methods
PL4146225T3 (pl) Związki metylotioniniowe do zastosowania w leczeniu hipoksemii
HK40115106A (en) Heterocyclic compounds for use in the treatment of cancer
IL287050A (en) Compounds for the treatment of oncovirus induced cancer and methods of use thereof
IL286649A (en) The history of quinoline and its use in cancer treatment
IL275906B (en) Use of heterocyclic substances to treat dark skin